导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -6.43% | 3474/4773 |
| 近一周 | -2.64% | 4561/5467 |
| 近一月 | 1.89% | 184/5421 |
| 近一季 | 3.27% | 500/5238 |
| 近半年 | -1.58% | 2004/4931 |
| 近一年 | -3.76% | 3081/4400 |
| 近两年 | 31.40% | 2210/2954 |
| 近三年 | 25.95% | 1250/2253 |
| 成立以来 | 128.62% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-8.77% 4320/4961 |
-4.43% 3507/5312 |
- - |
- - |
| 2025 | 10.27% 2825/4813 |
-1.29% 2626/3635 |
8.49% 331/4076 |
-1.79% 3967/4524 |
4.85% 476/4813 |
| 2024 | 33.49% 71/3463 |
3.47% 563/2808 |
1.80% 445/3014 |
24.52% 328/3129 |
1.78% 1028/3463 |
| 2023 | -5.05% 710/2656 |
-1.49% 1871/2280 |
0.60% 304/2385 |
4.36% 152/2515 |
-8.18% 2258/2655 |
| 2022 | -10.61% 211/2207 |
-5.39% 189/1919 |
-0.15% 1600/2016 |
-10.03% 338/2113 |
5.16% 483/2208 |
| 2021 | -4.81% 960/1822 |
-0.72% 388/1255 |
-1.50% 1171/1330 |
-3.51% 645/1466 |
0.88% 1049/1822 |
| 2020 | 13.64% 802/1250 |
-12.48% 889/1028 |
7.03% 848/1067 |
13.26% 332/1164 |
7.12% 727/1184 |
| 2019 | 35.55% 374/1092 |
25.66% 449/754 |
1.80% 109/804 |
-1.08% 631/850 |
7.12% 484/918 |
| 2018 | -15.13% 101/834 |
- - |
- - |
- - |
-8.64% 102/691 |
| 2017 | 21.28% 168/714 |
- - |
- - |
- - |
- - |
| 2016 | -5.21% 171/605 |
- - |
- - |
- - |
- - |
| 2015 | -6.44% 279/575 |
- - |
- - |
- - |
- - |
| 2014 | 82.70% 7/237 |
- - |
- - |
- - |
- - |
| 2013 | -8.32% 136/186 |
- - |
- - |
- - |
- - |
| 2012 | 22.43% 2/140 |
- - |
- - |
- - |
- - |
| 2011 | -13.75% 2/102 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 国投沪深300金融地产联接 VS. 长安沪深300非周期A(740101) |